Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

International Archives of Allergy and Immunology

Volumn 168, Issue 1, 2015, Pages 44-55

  Lumry, William R ^a   Farkas, Henriette ^b   Moldovan, Dumitru ^c   Toubi, Elias ^d   Baptista, Jovanna ^e   Craig, Timothy ^f   Riedl, Marc ^g  

^a AARA Research Center   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d BNAI ZION MEDICAL CENTER   (Israel)

^e SHIRE   (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abdominal; Acute treatment; C1 inhibitor deficiency; Cutaneous; FAST 3; Hereditary angioedema; Icatibant; Laryngeal; Open label extension

Indexed keywords

ICATIBANT; PLACEBO; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE HEREDITARY ANGIOEDEMA; NONCARDIAC CHEST PAIN; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL; PROCEDURES; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84946762400     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000441060     Document Type: Article

References (26)

1. Bork K, Staubach P, Eckardt AJ, Hardt J: Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619-627.
2. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W: Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-354.
3. Bork K, Hardt J, Witzke G: Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-697.
4. Cicardi M, Bergamaschini L, Cugno M, Beretta A, Zingale LC, Colombo M, Agostoni A: Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998; 199: 366-376.
5. Cugno M, Nussberger J, Cicardi M, Agostoni A: Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-317.
6. Bork K: Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010; 6: 15.
7. Cicardi M, Banerji A, Bracho F, et al: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
8. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A: Randomized placebocontrolled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-537.
9. Malbràn A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hebert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick H, Resnick D, Li H, Fernàndez Romero S, Lumry W: Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol 2014; 177: 544-553.
10. Bas M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013; 68: 1452-1459.
11. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B; HAWK (Hereditary Angioedema International Working Group): Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
12. Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
13. Banerji A: The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2013; 111: 329-336.
14. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT: The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-414.
15. Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE: Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc 2013; 34: 155-161.
16. Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, Packer F, Bernstein JA, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL: Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012; 33: 354-361.
17. Riedl MA, Levy RJ, Suez D, Lockey RF, Baker JW, Relan A, Zuraw BL: Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013; 110: 295-299.
18. Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA: Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol 2013; 110: 168-172.
19. Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL: C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks -final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-1611.
20. Bowen T, Cicardi M, Farkas H, et al: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
21. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
22. Zuraw B, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Riedl M: US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1: 458-467.
23. Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, Khan D, Sheikh J, Weldon D, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology: A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-Associated angioedema. J Allergy Clin Immunol 2013; 131: 1491-1493.
24. Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A; IOS Investigators: Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013; 8:e53773.
25. Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbràn A: Open-label, multicenter study of self-Administered icatibant for attacks of hereditary angioedema. Allergy 2014; 69: 305-314.
26. Farkas H, Csuka D, Zotter Z, Varga L, Böröcz Z, Temesszentandràsi G, Jakab L, Karàdi I: Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol 2012; 129: 851-852.